First-pass metabolism

Why can a drug that works well by injection do almost nothing when the same amount is swallowed?

Same molecule, same number of milligrams, same person, same afternoon. Into a vein it does what it is supposed to do. Swallowed, almost nothing happens.

Nothing about the chemistry changed between those two sentences, so the difference is not in the drug at all — it is in the journey. What does a swallowed molecule have to get through that an injected one does not?

Start with the plumbing, because the whole subject is one anatomical fact. Blood leaving the stomach and small intestine does not join the general circulation. It collects into the portal vein and goes to the liver — all of it, before a single molecule reaches the heart, the brain, or whatever tissue you were aiming at.

Why build a body that way? Ask what the gut is: the one place the outside world is deliberately let in. Routing that blood through the organ specialised in dismantling foreign molecules before it reaches everything else is sensible. A swallowed drug is simply a foreign molecule, and gets the treatment.

So the journey has gates, in a fixed order. First: does the drug enter the cells of the gut wall at all? That turns on whether it dissolves, whether it crosses membranes, whether acid or gut bacteria destroy it, and whether transporters pump it back out. Second: does it survive the gut wall, whose cells carry drug-metabolising enzymes of their own? Third: does it survive the liver on that single pass?

The gates are in series, so their effects multiply rather than add. Bioavailability — the fraction of the swallowed dose arriving intact in the general circulation — is therefore:

F = (fraction absorbed) x (fraction escaping the gut wall) x (fraction escaping the liver's first pass)

Multiply through with generous fractions. A drug getting four-fifths of the way through each of the first two gates has already lost about a third; let the liver remove three-quarters of what reaches it and roughly a sixth survives, with no gate behaving catastrophically. That is the answer to "almost nothing happens": nothing dramatic need occur for the product of three ordinary fractions to be small.

And the injection? Intravenously F is 1 by definition, the drug being placed in the very circulation the gates were guarding. It still meets the liver — but as a fraction of the cardiac output at a time, over and over, which is ordinary elimination. Same enzymes, same chemistry. The difference is that first pass hands the liver the entire dose at once.

That distinction earns its keep, because it predicts what will and will not change bioavailability. In the standard simplified model, the fraction the liver extracts depends on how fast blood delivers the drug and on the liver's intrinsic capacity to metabolise it. Where capacity vastly exceeds delivery, the liver takes nearly everything arriving, so bioavailability swings with liver blood flow or with a disease that shunts portal blood around the liver, while inhibiting the enzyme changes little. Where capacity is the smaller of the two, the enzyme is the binding constraint and the sensitivities reverse. Two drugs with identical bioavailability can therefore respond in opposite directions to the same event.

Which also shows how to avoid the toll: use a route whose blood does not drain to the portal vein — under the tongue, through the skin, inhaled, injected into muscle.

The nearest neighbour is steady-state-dosing.md, and the fixed point of difference is worth stating flatly. This piece is about how much of a single dose arrives; that one is about how much accumulates when doses are repeated. Bioavailability scales the amount entering per dose; it does not touch the half-life. drug-tolerance.md borders it too, since repeated exposure can induce the very enzymes doing the extracting — but tolerance is a counterweight the body builds, while first pass is a toll paid identically on the first dose and the thousandth. dose-response.md supplies the curve; bioavailability shifts where a swallowed dose lands on it without altering its shape.

One misconception to retire: that swallowing "wastes" a drug because stomach acid destroys it. Acid and bacterial degradation are real, but they are the first gate only, and for many drugs not where the loss is. The characteristic first-pass case is a drug absorbed perfectly well that simply never got past the liver.

Two caveats. Metabolites are not always inert: some drugs are given as inactive precursors precisely so the first pass converts them, and there the effect is the mechanism rather than the obstacle. And the flow-versus-capacity account is a deliberately simplified model.

Here is the test, done routinely. Give the same dose by vein and by mouth in the same person and compare total exposure over time; the ratio is F. If the shortfall is first-pass extraction rather than failed absorption, a route draining to systemic veins should recover most of it, and inhibiting the relevant gut or liver enzyme should raise oral exposure far more than intravenous. The everyday instance is grapefruit juice, which inhibits an enzyme in the gut wall and can markedly raise oral exposure to certain drugs while leaving an injected dose untouched.

The refuting observations are equally clean. If a portal-bypassing route gave the same poor exposure, the loss is at the first gate — absorption — and no enzyme manipulation will recover it. If an inhibitor raised oral and intravenous exposure alike, what is altered is general elimination, not the first pass. None of this is a reason to change how anyone takes anything: route, dose, and which combinations are safe is a clinical judgement.

• How liver disease can raise the effective dose of a swallowed drug without anyone changing the prescription.

Every term the collection defines is gathered in the glossary.